Drug Description in Trials / DrugBank / KEGG DRUG


Search results


No. Drug (Description in trials) DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY Disease ID
1Interferons, glatiramer acetate, teriflunomide, dimethyl fumarate, alemtuzumab, cladribine, fingolimod, ponesimod, rituximab, ocrelizumab, ofatumumab, natalizumab[12] Acetate,
Alemtuzumab,
Cladribine,
Dimethyl fumarate,
Fingolimod,
Glatiramer,
Natalizumab,
Ocrelizumab,
Ofatumumab,
Ponesimod,
Rituximab,
Teriflunomide
[10] Cladribine ,
Alemtuzumab ,
Rituximab ,
Dimethyl fumarate ,
Ocrelizumab ,
Natalizumab ,
Ofatumumab ,
Fingolimod ,
Teriflunomide ,
Ponesimod 💬
[7] CD52,
DHODH,
ITGA4,
KEAP1,
MS4A1,
RRM1,
S1PR1 💬
[30] Arrhythmogenic right ventricular cardiomyopathy, Biosynthesis of cofactors, Cell adhesion molecules, Chemical carcinogenesis - reactive oxygen species, Dilated cardiomyopathy, Drug metabolism - other enzymes, ECM-receptor interaction, Fluid shear stress and atherosclerosis, Focal adhesion, FoxO signaling pathway, Glutathione metabolism, Hematopoietic cell lineage, Hepatocellular carcinoma, Human papillomavirus infection, Hypertrophic cardiomyopathy, Intestinal immune network for IgA production, Leishmaniasis, Leukocyte transendothelial migration, Metabolic pathways, Neuroactive ligand-receptor interaction, Nucleotide metabolism, PI3K-Akt signaling pathway, Parkinson disease, Pathways in cancer, Purine metabolism, Pyrimidine metabolism, Regulation of actin cytoskeleton, Sphingolipid signaling pathway, Ubiquitin mediated proteolysis, Yersinia infection 💬[1] 13 💬
2PONESIMOD[1] Ponesimod[1] Ponesimod 💬[1] S1PR1 💬[3] FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬[1] 13 💬
3Ponesimod 10 mg[1] Ponesimod[1] Ponesimod 💬[1] S1PR1 💬[3] FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬[1] 13 💬
4Ponesimod 20 mg[1] Ponesimod[1] Ponesimod 💬[1] S1PR1 💬[3] FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬[1] 13 💬
5Ponesimod 40 mg[1] Ponesimod[1] Ponesimod 💬[1] S1PR1 💬[3] FoxO signaling pathway, Neuroactive ligand-receptor interaction, Sphingolipid signaling pathway 💬[1] 13 💬